CSPC Pharmaceutical (1093.HK): Focus on the Ascending Triangle

CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.

Charts (2)

CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.

After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.


Source: GAIN Capital, TradingView

On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.

In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.

In this case, the reader should consider a neutral bias and focus on the breakout signal in the future. 

A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.

In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).

More from Equities

Join our live webinars for the latest analysis and trading ideas. Register now

GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.